Clinical trial
Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis
NCT00125333 · Anesiva, Inc., Industry · Completed
Key facts
| NCT number | NCT00125333 |
|---|---|
| Title | Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis |
| Official title | A Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety of Repeated Topical Application of Three Concentrations of NF-kappaB Decoy in Adults With Mild-to-Moderate Atopic Dermatitis |
| Lead sponsor | Anesiva, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Atopic Dermatitis |
| Intervention type | Drug |
| Interventions | NF-kappaB Decoy |
| Enrollment | 75 |
| Start date | Mar 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Aug 1, 2005 |
| Last update posted | Nov 19, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: